Case Report
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 26, 2025; 13(6): 98084
Published online Feb 26, 2025. doi: 10.12998/wjcc.v13.i6.98084
Anlotinib-induced sick sinus syndrome: Two case reports
Cheng-Feng Fu, Li-Fen Yang, Lei Tian, Song Deng, Qi Zhang, Biao Yao
Cheng-Feng Fu, Li-Fen Yang, Lei Tian, Song Deng, Biao Yao, Department of Oncology, Tongren People’s Hospital, Tongren 554300, Guizhou Province, China
Qi Zhang, Department of Oncology, Guizhou Provincial People’s Hospital, Guiyang 550000, Guizhou Province, China
Author contributions: Fu CF designed the report; Yang LF, Tian L, and Deng S collected the patients’ clinical data; Yao B provided key intellectual discussions; Zhang Q performed the final revision and translation of the manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qi Zhang, Associate Chief Physician, PhD, Department of Oncology, Guizhou Provincial People’s Hospital, No. 83 Zhongshan East Road, Nanming District, Guiyang 550000, Guizhou Province, China. kekexinqing@163.com
Received: June 18, 2024
Revised: October 12, 2024
Accepted: November 7, 2024
Published online: February 26, 2025
Processing time: 159 Days and 20.1 Hours
Core Tip

Core Tip: This case report presents the first known instances of sick sinus syndrome associated with the use of anlotinib in patients with non-small cell lung cancer, emphasizing the importance of cardiac monitoring during treatment. The report compares two different management approaches for anlotinib-induced sick sinus syndrome, one with a dual-chamber permanent pacemaker and the other with medication discontinuation, providing valuable insights for clinical practice.